Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major
暂无分享,去创建一个
D J Pennell | D. Pennell | L. Anderson | M. Tanner | M. Roughton | M. Westwood | J. M. Walker | D. Wu | P. Kirk | J. Porter | J. Patel | D. Wu | J. Taylor | J. M. Walker | P Kirk | M Roughton | J B Porter | J M Walker | M A Tanner | J Patel | D Wu | J Taylor | M A Westwood | L J Anderson | J. Patel | D. Pennel | Dianne Wu | Jane Taylor | Jane Taylor | Junaid Patel
[1] D. Pennell,et al. A Randomized, Placebo-Controlled, Double-Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance , 2007, Circulation.
[2] A. Nicolucci,et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. , 2002, Blood.
[3] J. H. MacMillan,et al. Survival in medically treated patients with homozygous beta-thalassemia. , 1994, The New England journal of medicine.
[4] W. Hofmann,et al. WT1-Peptide Vaccination Shows High Immunogenicity and Clinical Activity in Patients with Acute Myeloid Leukemia. , 2005 .
[5] T. Coates,et al. Longitudinal analysis of heart and liver iron in thalassemia major. , 2008, Blood.
[6] David N. Firmin,et al. Intercentre Reproducibility of Magnetic Resonance T2* Measurements of Myocardial Iron in Thalassaemia , 2005, The International Journal of Cardiovascular Imaging.
[7] C. McLaren,et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. , 1994, The New England journal of medicine.
[8] J. H. MacMillan,et al. Survival in Medically Treated Patients with Homozygous β-Thalassemia , 1994 .
[9] T. Coates,et al. MRI detects myocardial iron in the human heart , 2006, Magnetic resonance in medicine.
[10] Matthew Darlison,et al. Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register , 2000, The Lancet.
[11] Matthew W. Darlison,et al. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance , 2008, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.
[12] David J. Weatherall,et al. Oxford textbook of medicine , 1996 .
[13] H. Calkins,et al. ACC/AHA/HRS 2006 key data elements and definitions for electrophysiological studies and procedures: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (ACC/AHA/HRS Writing Committee to Develop Data Standards on Electrophysiology). , 2006, Journal of the American College of Cardiology.
[14] M. Hentze,et al. Ca2+ channel blockers reverse iron overload by a new mechanism via divalent metal transporter-1 , 2007, Nature Medicine.
[15] D. Pennell,et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance , 2004, British journal of haematology.
[16] Hugh Calkins,et al. ACC/AHA/HRS 2006 key data elements and definitions for electrophysiological studies and procedures: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (ACC/AHA/HRS Writing Committee to Develop Data Standards on Electrophysiology). , 2006, Circulation.
[17] L. Wilkins. ACC/AHA/HRS 2006 Key Data Elements and Definitions for Electrophysiological Studies and Procedures , 2006 .
[18] W. Roberts,et al. Iron in the heart. Etiology and clinical significance. , 1971, The American journal of medicine.
[19] D N Firmin,et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. , 2001, European heart journal.
[20] D. Pennell,et al. Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. , 2006, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.
[21] L. Russel Cecil,et al. Textbook of Medicine , 1932 .
[22] D. Pennell,et al. Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial iron , 2007, Journal of magnetic resonance imaging : JMRI.
[23] John B. Porter,et al. Myocardial T2* in Patients with Cardiac Failure Secondary to Iron Overload. , 2005 .
[24] D. Pennell,et al. A single breath‐hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload , 2003, Journal of magnetic resonance imaging : JMRI.
[25] P. Jarritt,et al. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. , 2004, Blood.
[26] Thomas D. Coates,et al. Cardiac Iron Determines Cardiac T2*, T2, and T1 in the Gerbil Model of Iron Cardiomyopathy , 2005, Circulation.
[27] D. Pennell,et al. Journal of Cardiovascular Magnetic Resonance Open Access Combined Chelation Therapy in Thalassemia Major for the Treatment of Severe Myocardial Siderosis with Left Ventricular Dysfunction , 2008 .
[28] A. Cnaan,et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. , 2004, Haematologica.
[29] N. Khaper,et al. Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy , 2006, Journal of Molecular Medicine.
[30] Marvin D Nelson,et al. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. , 2004, Blood.
[31] Mark A Westwood,et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. , 2006, Blood.
[32] Dudley J. Pennell,et al. Cardiovascular Magnetic Resonance , 2010, Circulation.